These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
492 related articles for article (PubMed ID: 30671808)
1. The efficacy and safety of lenvatinib for advanced hepatocellular carcinoma in a real-world setting. Obi S; Sato T; Sato S; Kanda M; Tokudome Y; Kojima Y; Suzuki Y; Hosoda K; Kawai T; Kondo Y; Isomura Y; Ohyama H; Nakagomi K; Ashizawa H; Miura Y; Amano H; Mochizuki H; Omata M Hepatol Int; 2019 Mar; 13(2):199-204. PubMed ID: 30671808 [TBL] [Abstract][Full Text] [Related]
2. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma. Ikeda K; Kudo M; Kawazoe S; Osaki Y; Ikeda M; Okusaka T; Tamai T; Suzuki T; Hisai T; Hayato S; Okita K; Kumada H J Gastroenterol; 2017 Apr; 52(4):512-519. PubMed ID: 27704266 [TBL] [Abstract][Full Text] [Related]
3. Optimal management of patients with hepatocellular carcinoma treated with lenvatinib. Ikeda M; Kobayashi M; Tahara M; Kaneko S Expert Opin Drug Saf; 2018 Nov; 17(11):1095-1105. PubMed ID: 30264594 [TBL] [Abstract][Full Text] [Related]
4. Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma. Ikeda M; Okusaka T; Mitsunaga S; Ueno H; Tamai T; Suzuki T; Hayato S; Kadowaki T; Okita K; Kumada H Clin Cancer Res; 2016 Mar; 22(6):1385-94. PubMed ID: 26500236 [TBL] [Abstract][Full Text] [Related]
5. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Kudo M; Finn RS; Qin S; Han KH; Ikeda K; Piscaglia F; Baron A; Park JW; Han G; Jassem J; Blanc JF; Vogel A; Komov D; Evans TRJ; Lopez C; Dutcus C; Guo M; Saito K; Kraljevic S; Tamai T; Ren M; Cheng AL Lancet; 2018 Mar; 391(10126):1163-1173. PubMed ID: 29433850 [TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT. Okusaka T; Ikeda K; Kudo M; Finn R; Qin S; Han KH; Cheng AL; Piscaglia F; Kobayashi M; Sung M; Chen M; Wyrwicz L; Yoon JH; Ren Z; Mody K; Dutcus C; Tamai T; Ren M; Hayato S; Kumada H J Gastroenterol; 2021 Jun; 56(6):570-580. PubMed ID: 33948712 [TBL] [Abstract][Full Text] [Related]
7. Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial. Vogel A; Qin S; Kudo M; Su Y; Hudgens S; Yamashita T; Yoon JH; Fartoux L; Simon K; López C; Sung M; Mody K; Ohtsuka T; Tamai T; Bennett L; Meier G; Breder V Lancet Gastroenterol Hepatol; 2021 Aug; 6(8):649-658. PubMed ID: 34087115 [TBL] [Abstract][Full Text] [Related]
8. Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma. Kirino S; Tsuchiya K; Kurosaki M; Kaneko S; Inada K; Yamashita K; Osawa L; Hayakawa Y; Sekiguchi S; Okada M; Wang W; Higuchi M; Takaura K; Maeyashiki C; Tamaki N; Yasui Y; Nakanishi H; Itakura J; Takahashi Y; Asahina Y; Izumi N PLoS One; 2020; 15(4):e0231828. PubMed ID: 32310967 [TBL] [Abstract][Full Text] [Related]
9. Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer. Cabanillas ME; Takahashi S Semin Oncol; 2019 Feb; 46(1):57-64. PubMed ID: 30685073 [TBL] [Abstract][Full Text] [Related]
10. Impact of Relative Dose Intensity of Early-phase Lenvatinib Treatment on Therapeutic Response in Hepatocellular Carcinoma. Takahashi A; Moriguchi M; Seko Y; Ishikawa H; Yo T; Kimura H; Fujii H; Shima T; Mitsumoto Y; Ishiba H; Takashima H; Nagao Y; Jo M; Arai M; Hara T; Okajima A; Muramatsu A; Morita A; Yoshinami N; Nakajima T; Mitsuyoshi H; Umemura A; Nishikawa T; Yamaguchi K; Itoh Y Anticancer Res; 2019 Sep; 39(9):5149-5156. PubMed ID: 31519627 [TBL] [Abstract][Full Text] [Related]
11. Reduction in Tumor Stain at 2 Weeks after Treatment Initiation Is a Predictor of the Efficacy of Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma. Kunimoto H; Shakado S; Tanaka T; Takata K; Yamauchi R; Fukuda H; Tsuchiya N; Yokoyama K; Morihara D; Takeyama Y; Hirai F; Sakisaka S Oncology; 2020; 98(11):779-786. PubMed ID: 32877911 [TBL] [Abstract][Full Text] [Related]
12. Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes. Haddad RI; Schlumberger M; Wirth LJ; Sherman EJ; Shah MH; Robinson B; Dutcus CE; Teng A; Gianoukakis AG; Sherman SI Endocrine; 2017 Apr; 56(1):121-128. PubMed ID: 28155175 [TBL] [Abstract][Full Text] [Related]
13. Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma. Kim S; Kim KH; Kim BK; Park JY; Ahn SH; Kim DY; Kim SU J Gastroenterol Hepatol; 2021 May; 36(5):1317-1325. PubMed ID: 33217054 [TBL] [Abstract][Full Text] [Related]
14. [Value of lenvatinib for the treatment of advanced hepatocellular carcinoma]. Yuan B; Wang Y; Zhang JL; Yan JY; Yuan K; Wang XQ; Fu JX; Duan F; Wang MQ Zhonghua Yi Xue Za Zhi; 2020 Mar; 100(11):833-836. PubMed ID: 32234154 [No Abstract] [Full Text] [Related]
15. Ramucirumab for advanced hepatocellular carcinoma in the current real world: a Japanese single-arm study post-REACH-2 (The R-evolution study). Kobayashi K; Ogasawara S; Itobayashi E; Okubo T; Itokawa N; Nakamura K; Moriguchi M; Watanabe S; Ikeda M; Kuroda H; Kawaoka T; Hiraoka A; Yasui Y; Kuzuya T; Sato R; Kanzaki H; Koroki K; Inoue M; Nakamura M; Kiyono S; Kanogawa N; Kondo T; Nakamoto S; Ozawa Y; Tsuchiya K; Atsukawa M; Aikata H; Aramaki T; Oka S; Morimoto N; Kurosaki M; Itoh Y; Izumi N; Kato N Invest New Drugs; 2024 Aug; 42(4):394-404. PubMed ID: 38842657 [TBL] [Abstract][Full Text] [Related]
16. Lenvatinib: A Review in Hepatocellular Carcinoma. Al-Salama ZT; Syed YY; Scott LJ Drugs; 2019 Apr; 79(6):665-674. PubMed ID: 30993651 [TBL] [Abstract][Full Text] [Related]
17. Sorafenib Kuzuya T; Ishigami M; Ito T; Ishizu Y; Honda T; Ishikawa T; Fujishiro M Anticancer Res; 2020 Apr; 40(4):2283-2290. PubMed ID: 32234927 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of tislelizumab plus lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma: a multicenter, single-arm, phase 2 trial. Xu L; Chen J; Liu C; Song X; Zhang Y; Zhao H; Yan S; Jia W; Wu Z; Guo Y; Yang J; Gong W; Ma Y; Yang X; Gao Z; Zhang N; Zheng X; Li M; Su D; Chen M BMC Med; 2024 Apr; 22(1):172. PubMed ID: 38650037 [TBL] [Abstract][Full Text] [Related]
19. Association of lenvatinib plasma concentration with clinical efficacy and adverse events in patients with hepatocellular carcinoma. Hata K; Suetsugu K; Egashira N; Makihara Y; Itoh S; Yoshizumi T; Tanaka M; Kohjima M; Watanabe H; Masuda S; Ieiri I Cancer Chemother Pharmacol; 2020 Dec; 86(6):803-813. PubMed ID: 33095285 [TBL] [Abstract][Full Text] [Related]
20. Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience. Wu WC; Lin TY; Chen MH; Hung YP; Liu CA; Lee RC; Huang YH; Chao Y; Chen SC Invest New Drugs; 2022 Aug; 40(4):789-797. PubMed ID: 35477812 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]